Clare West
22 July 2021
Clare West guides you through the data available in the Open Targets informatics tools, with particular focus on the Genetics Portal.
The PROTACtable genome: a systematic assessment of drug target tractabilityHelena Cornu
21 July 2021
An Open Targets project has created a framework to assess whether human proteins could be targeted using Proteolysis Targeting Chimeras (PROTACs).
Summer School: A Crash Course in Open Targets, Part 1Clare West
15 July 2021
Clare West guides you through how to access data from the Open Targets Platform and Genetics Portal using the web interface and GraphQL API
Open Targets Genetics: Version 5 is out!Open Targets Outreach
30 June 2021
Open Targets Platform 21.06 has been released!Open Targets Outreach
30 June 2021
Building the Open Targets Platform Interface using ReactAlfredo Miranda
3 June 2021
The Open Targets Platform's user interface uses React and JavaScript to present the data produced by the ETL and served through the API.
Presenting Open Targets to the World via Play, Elasticsearch, Clickhouse and GraphQLCinzia Malangone, Jarrod Baker
27 May 2021
The next-generation Platform involved a switch from REST to a GraphQL API. Here we discuss the technology used, including Elasticsearch and Clickhouse.
Wheat from the chaff: extracting, transforming, and loading data for Open TargetsJarrod Baker, Cinzia Malangone
20 May 2021
The Open Targets Platform features a new ETL pipeline, written in Scala and Spark. Here we detail the purpose of the pipeline, and the technology it is based on.
Towards a reproducible ETL: an overview of Open Targets' platform inputsCinzia Malangone, Jarrod Baker
13 May 2021
A discussion of how Platform Input support ensures reproducible inputs for our Extract-Transform-Load (ETL) pipeline.
Beyond associations: building therapeutic hypotheses with Open TargetsIan Dunham, David Hulcoop
6 May 2021
Open Targets directors describe the elements of a full therapeutic hypothesis, and how Open Targets is working to enable the systematic assessment of such hypotheses.
The next-generation Open Targets Platform: rebuilt, redesigned, reimaginedHelena Cornu
29 April 2021
The next-gen Platform presents an improved user experience. It has been rebuilt with leading-edge technologies including Scala, Spark, and React, and includes new features and data.
How we improved our experimental data curation during the COVID-19 lockdownPanos Zalmas
22 April 2021
Thanks to the expertise of our lab-based research colleagues, we made valuable contributions to our target validation projects in neurodegeneration and immunology & immflammation.
Q&A with Babatomiwa Adebiyi, an intern with the Open Targets PlatformHelena Cornu, David Ochoa
16 April 2021
Babatomiwa Adebiyi is a computer science student at MIT. He tell us about his machine learning project to prioritise targets in our main therapeutic areas: cancer, immune diseases, and neurological diseases
Job seeking during the pandemic: a Q&A with Kostas TsirigosKostas Tsirigos
26 March 2021
How do you prepare for a virtual interview? What is the remote onboarding process like? Open Targets project manager Kostas Tsirigos tells us about his experience.
Open Targets hosts Kiran Musunuru: insights into the genetic basis of coronary heart diseaseHelena Cornu
16 March 2021
An insight into Kiran Musunuru's career, from identifying mutations in ANGPTL3 that protect against heart disease, to working on a "vaccination" against heart attacks, and more.
Sharing is caring: why we need more freely available cancer GWAS summary statisticsAnnalisa Buniello
11 March 2021
Though progress has been made to integrate summary statistics into the GWAS Catalog, we make the case for increasing the submission rate for GWAS studies in cancer cohorts.
Getting a finer view on genes leading to Alzheimer’s disease riskHelena Cornu, Jeremy Schwartzentruber
5 March 2021
New research from Open Targets identifies new genetic regions associated with Alzheimer's disease by integrating multiple layers of omics data.
Rewriting the Open Targets Platform's Drug IndexJarrod Baker
2 March 2021
The Open Targets Platform maintains an index of molecules with drug-like properties. We discuss of the development of that dataset.
How Open Targets is investigating 100 chromatin-related disorders | Rare Disease Day 2021Sebastian Gerety
28 February 2021
Neurodevelopmental disorders are rare, but a project led by Sebastian Gerety is illuminating their molecular mechanisms by studying many rare diseases at once.
The Beta version of the next-generation Open Targets Platform has been released!Helena Cornu
26 February 2021
The new Platform beta reinvents the best of the old Platform with a redesigned experience and improved usability.